



November 30, 2024

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

BSE Limited

P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Symbol: LUPIN

Scrip Code: Equity - 500257

Dear Sir/Madam,

Subject: Clarification /confirmation on the news item appearing in www.business-standard.com

This is with reference to e-mail received from BSE bearing reference no. L/SURV/ONL/RV/ARJ/ (2024-2025)/ 115 and the letter received from NSE, bearing reference no. NSE/CM/Surveillance/15000, both dated November 29, 2024, seeking clarification/confirmation on the news item appeared in the www.business-standard.com captioned "Lupin shares gain 3% after USFDA approves type-2 diabetes drug; details".

In this regard we would like to state as under:

1. We confirm that the Company has received **tentative approval** from U.S. FDA for Sitagliptin and Metformin Hydrochloride Tablets to market a generic equivalent of Janumet® Tablets, 50 mg/500 mg and 50 mg/1000 mg of Merck Sharp & Dohme LLC.

As the said event was not material as defined under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the same was not disclosed to the Stock Exchanges as required under the said Regulation.

2. The Company is not aware of any information that has not been announced to the Stock Exchanges which could explain the movement in the trading.
3. We confirm that there is no material impact of the above reported news on the Company.

In compliance with Regulation 30 of the SEBI Listing Regulations, the Company makes prompt disclosures, as and when any event or information is considered material or warrants such disclosure under the said Regulations and shall continue to do so.

This is for your information and records.

Thanking you,

For LUPIN LIMITED

AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICE
(ACS -15754)

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com